VANCOUVER, BC, May 6, 2025 /PRNewswire/ – New global reports on the Spine and Vertebral Compression Fracture (VCF), along with Minimally Invasive Spine Surgery (MIS) markets, from iData Research reveal major shifts reshaping the industry. The global spinal implant and VCF market is projected to grow from $21.4 billion in 2024 to nearly $32 billion by 2031, alongside the minimally invasive spinal (MIS) implant market’s rise from $4 billion in 2024 to nearly $6 billion by 2031.
Produced by iData Research, a leading medical device market intelligence firm, these reports provide crucial insights for orthopedic, neurosurgical, and spine device leaders navigating competitive pricing, regulatory shifts, outpatient migration, and surgical innovation.
“With spinal disorders like degenerative disc disease and stenosis becoming more prevalent, especially among aging populations, spine device companies need precise, actionable intelligence, ” said Dr. Kamran Zamanian, CEO of iData Research. “Our latest reports give business leaders the insights they need – from understanding where pricing pressures hit hardest to tracking regional MIS adoption – so they can respond with precision and stay competitive in a rapidly evolving $38B market.”
Global Spine Surgery Market Surges Amid 600M LBP Cases, Driven by MIS Innovation and Asia-Pacific Growth
Low back pain (LBP) is one of the most common and debilitating health challenges worldwide affecting more than 600 million people. Millions suffer from spinal conditions like disc herniation, stenosis, or vertebral compression fractures (VCFs), often requiring surgical intervention.
The global spinal implant and VCF market continues to grow, driven by demand for faster, safer, and more cost-effective spine procedures. However, growth is uneven – while Asia-Pacific continues to expand its lead, mature markets like North America are experiencing pricing compression, regulatory shifts, and procedure migration to outpatient settings.
In parallel, minimally invasive spine surgery is gaining traction worldwide. MIS procedures offer shorter recovery times, less trauma, and fewer complications, making them especially appealing for elderly patients and overburdened healthcare systems. Despite a steep learning curve, MIS pedicle screws, interbody devices, and spine endoscopes are now driving growth in the segment – projected to reach nearly $6 billion by 2031.
The Global Spine and VCF and Global MIS Spinal Implant market reports include in-depth insights from 65+ countries across 7 regions: North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Africa, and Asia-Pacific.
Key Insights from the Report:
Who Should Read This Report?
This report is designed for CEOs, CFOs, product and marketing managers, as well as strategic decision-makers in the spine and orthopedic device sectors seeking actionable insights on technology adoption and procedural migration trends.
Explore the Market Report
Access a Sample of the Full Global Spinal Implants and VCF, or a Sample of the Full Global Minimally Invasive Spine Surgery market reports, or contact marketing at marketing@idataresearch.net to learn more and see detailed insights into market drivers, growth projections, and strategic opportunities.
About iData Research iData Research has been a leader in market intelligence for the medical device industry for over 20 years, delivering data-driven insights that help companies mitigate market risks, optimize pricing strategies, and uncover new revenue opportunities.
Learn more at https://idataresearch.com/
SOURCE iData Research Inc.
– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI)…
D-bal-max D-Bal MAX Glasgow, June 15, 2025 (GLOBE NEWSWIRE) -- In the quest for enhanced…
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment…
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response…
After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients…
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were…